{
    "clinical_study": {
        "@rank": "90643", 
        "acronym": "ASTER", 
        "arm_group": [
            {
                "arm_group_label": "Arm A: Losartan", 
                "arm_group_type": "Active Comparator", 
                "description": "Arm A: Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide ) + Losartan 50mg*2/day until the halting for any reason"
            }, 
            {
                "arm_group_label": "Arm B: Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Arm B: Standard of care (Radiotherapy  with concomitant temozolomide followed by monthly cures of temozolomide + Placebo 2/day until the halting for any reason"
            }
        ], 
        "brief_summary": {
            "textblock": "To assess the efficacy of an Angiotensin-II inhibitor (Losartan) to reduce peritumoral edema\n      in newly diagnosed glioblastoma patients."
        }, 
        "brief_title": "Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Newly-diagnosed Glioblastoma", 
        "condition_browse": {
            "mesh_term": "Glioblastoma"
        }, 
        "detailed_description": {
            "textblock": "Multicentre, randomized (1:1), double blinded trial:- Arm A: Standard of care (Radiotherapy\n      with concomitant temozolomide followed by monthly cures of temozolomide ) + Losartan\n      50mg*2/day until the halting for any reason - Arm B: Standard of care (Radiotherapy  with\n      concomitant temozolomide followed by monthly cures of temozolomide + Placebo 2/day until the\n      halting for any reason."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 years or older\n\n          -  Histologically confirmed glioblastoma (Grade 4 WHO)\n\n          -  patients eligible for radiotherapy and concomitant Temozolomide\n\n          -  KPS \u2265 50%\n\n          -  Adequate hematologic, liver and renal functions\n\n        Exclusion Criteria:\n\n          -  Patients unable to undergo an MRI with contrast\n\n          -  Patients without any residual tumor left on the screening MRI of both flair and\n             contrast-enhanced lesions complete surgical resection)\n\n          -  Any prior treatment of glioblastoma including any local therapy (immunotherapy,\n             Gliadel wafers, \u2026..) during or after surgical resection\n\n          -  Any on-going treatment for high blood pressure at time of inclusion, whatever the\n             therapeutic class of drugs\n\n          -  Systolic blood pressure <110 mmHg.\n\n          -  relative or definite contra-indication to Losartan:\n\n          -  Pregnant or breast feeding women; Women with an intact uterus (unless amenorrhoeic\n             for the last 24 months) not using effective means of contraception\n\n          -  Non-affiliation to the \"s\u00e9curit\u00e9 sociale\""
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01805453", 
            "org_study_id": "P120105", 
            "secondary_id": "2012-004536-34"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm A: Losartan", 
                "description": "Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide ) + Losartan or placebo (Arm A or B) 50mg*2/day until the halting for any reason", 
                "intervention_name": "Losartan", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm B: Placebo", 
                "description": "Standard of care (Radiotherapy  with concomitant temozolomide followed by monthly cures of temozolomide + Placebo 2/day until the halting for any reason", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Angiotensin II", 
                "Losartan", 
                "Temozolomide", 
                "Angiotensin Receptor Antagonists"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Glioblastoma", 
            "Angiotensin-II inhibitors", 
            "Losartan", 
            "steroids", 
            "Radiotherapy", 
            "Edema", 
            "Randomized trial"
        ], 
        "lastchanged_date": "May 30, 2014", 
        "location": {
            "contact": {
                "email": "antoine.carpentier@avc.aphp.fr", 
                "last_name": "Antoine CARPENTIER, MD, PhD", 
                "phone": "+33 1 48 95 54 91"
            }, 
            "facility": {
                "address": {
                    "city": "Bobigny", 
                    "country": "France", 
                    "zip": "93000"
                }, 
                "name": "Neurology Department - Avicenne Hospital"
            }, 
            "investigator": {
                "last_name": "Antoine CARPENTIER, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma- A Randomized Multicenter Trial", 
        "overall_contact": {
            "email": "antoine.carpentier@avc.aphp.fr", 
            "last_name": "Antoine CARPENTIER, MD, PhD", 
            "phone": "+33 1 48 95 54 91"
        }, 
        "overall_official": {
            "affiliation": "Assistance Publique - H\u00f4pitaux de Paris", 
            "last_name": "Antoine CARPENTIER, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Steroid dosage required to control brain edema on the last day of radiotherapy in each arm", 
            "safety_issue": "Yes", 
            "time_frame": "Up to Day 42+ 1 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01805453"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Steroids dosage 1 month after the end of RT", 
                "safety_issue": "Yes", 
                "time_frame": "Day 42+ 1 month"
            }, 
            {
                "measure": "Assessment of cerebral edema on MRI", 
                "safety_issue": "Yes", 
                "time_frame": "Day -28 at -13, Day 42, Day 42+1 month"
            }, 
            {
                "description": "To be reported according to NCI/CTC version 3.0 (adverse events)", 
                "measure": "Tolerance (NCI-CTCAE v3.0)", 
                "safety_issue": "Yes", 
                "time_frame": "up to day42 +1 month + 7 days"
            }, 
            {
                "measure": "Blood pressure", 
                "safety_issue": "Yes", 
                "time_frame": "Day -10 at -7, Day0, 42, Day 42+1month"
            }, 
            {
                "measure": "HbA1C", 
                "safety_issue": "Yes", 
                "time_frame": "Day -10 at -7, D42, Day 42+1month"
            }, 
            {
                "measure": "glycemia", 
                "safety_issue": "Yes", 
                "time_frame": "Day -10 at -7, Day14, 28, 42, Day 42+1month"
            }, 
            {
                "measure": "body weight", 
                "safety_issue": "Yes", 
                "time_frame": "Day -10 at -7, Day42, Day 42+1month"
            }, 
            {
                "measure": "side-effects of steroids", 
                "safety_issue": "Yes", 
                "time_frame": "up to day42 +1 month"
            }, 
            {
                "measure": "Executive functions ( \" Moca test \")", 
                "safety_issue": "Yes", 
                "time_frame": "Day-10 at -7, Day 42, Day 42+1 month"
            }, 
            {
                "measure": "Quality of life (EORTC)", 
                "safety_issue": "Yes", 
                "time_frame": "Day-10 at -7, Day 42, Day 42+1 month"
            }
        ], 
        "source": "Assistance Publique - H\u00f4pitaux de Paris", 
        "sponsors": {
            "collaborator": {
                "agency": "ANOCEF (french association of neuro-oncologists)", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Assistance Publique - H\u00f4pitaux de Paris", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}